Integrated scRNA-Seq and functional profiling reveal CD52 as a driver of pancreatic ductal adenocarcinoma metastasis and immunosuppression.

A newly identified protein drives pancreatic cancer spread and immune suppression, offering a fresh therapeutic target in this devastating disease.

Integrated single-cell RNA sequencing and functional profiling identify CD52 as a novel driver of PDAC metastasis and immunosuppression, representing a potential therapeutic target in this aggressive malignancy with extremely limited treatment options.

What the study was

Study design

translational

Category

novel_therapeutics

Maturity

translational

Journal

Oncogenesis

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.